Personal CFO Solutions LLC increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 10.3% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,177 shares of the medical research company’s stock after buying an additional 110 shares during the quarter. Personal CFO Solutions LLC’s holdings in IQVIA were worth $265,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently bought and sold shares of IQV. Old North State Trust LLC raised its stake in IQVIA by 342.2% during the 1st quarter. Old North State Trust LLC now owns 597 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 462 shares during the last quarter. Live Oak Investment Partners acquired a new position in IQVIA during the 4th quarter valued at $41,000. MBM Wealth Consultants LLC acquired a new position in IQVIA during the 4th quarter valued at $51,000. KB Financial Partners LLC acquired a new position in IQVIA during the 1st quarter valued at $53,000. Finally, Ten Capital Wealth Advisors LLC acquired a new position in IQVIA during the 1st quarter valued at $54,000. 86.82% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other IQVIA news, insider Constantinos Panagos sold 27,317 shares of the stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $208.67, for a total transaction of $5,700,238.39. Following the sale, the insider now owns 14,250 shares of the company’s stock, valued at approximately $2,973,547.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.50% of the company’s stock.
IQVIA Stock Up 0.2 %
Analysts Set New Price Targets
A number of brokerages have recently issued reports on IQV. Barclays dropped their price objective on shares of IQVIA from $245.00 to $215.00 and set an “overweight” rating for the company in a research note on Thursday, November 2nd. HSBC began coverage on shares of IQVIA in a research note on Wednesday, September 6th. They issued a “buy” rating and a $260.00 price objective for the company. Truist Financial dropped their price objective on shares of IQVIA from $260.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, November 3rd. Mizuho dropped their price objective on shares of IQVIA from $250.00 to $229.00 and set a “buy” rating for the company in a research note on Tuesday, October 10th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $262.00 to $239.00 and set an “overweight” rating for the company in a research note on Monday, November 13th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $236.57.
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Five stocks we like better than IQVIA
- How to Calculate Inflation Rate
- Safeguard your portfolio with these three bargain stocks
- The How And Why of Investing in Oil Stocks
- Membership clubs gain leverage for the consumer rebound
- Why is the Ex-Dividend Date Significant to Investors?
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.